In this SOHO Insider podcast, host Saad Usmani, MD, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, spoke with Roberto Mina, MD, associate professor of hematology at Emory University, on news from the 2026 ASCO Annual Meeting.

The conversation highlighted a presentation by Dr. Roberto Mina regarding the pivotal phase 3 MajesTEC-9 trial evaluating teclistamab monotherapy for patients with relapsed/refractory multiple myeloma who were previously exposed to lenalidomide and anti-CD38 antibodies

Follow more news from ASCO here.

In this SOHO Insider podcast, host Megan Melody, MD, from Tampa General Hospital, spoke with Nirav Shah, MD, professor at the Medical College of Wisconsin, on news from the 2026 Tandem Meetings, including updates on dual-targeted CAR T-cell results in CLL and interim phase 2 data on zamtocabtagene autoleucel (zamto-cel) in in transplant-ineligible patients with DLBCL.

Of dual-targeting CAR-T cell therapies, he said, “I think this is the next iteration in CAR. Zamtocabtagene is one of four 20/19 CARs under development and if you look at the data for all of them, they look to be highly efficacious, better than our standard CD19-CAR.”

Listen to more podcasts on sohoinsider.com.

The second session of the Community Oncology Brown Bag Series, hosted by SOHO Insider, held on February 11, 2026, and featured guest speaker Tara Graff, DO, MS, at Mission Cancer + Blood and director of their clinical research program. Dr. Graff discussed “Moving CAR T-cell therapies into the community setting.”

This program is led by Loretta Nastoupil, MD, the SOHO Insider community oncology section editor.

To register for the series, go to https://soho.click/community-oncology-series

Gloria Iacoboni, MD, PhD, a hematologist at Vall d’Hebron University Hospital in Barcelona, Spain, spoke with Dr. James Day, a clinical research training fellow at UCL in London, during this SOHO Insider podcast episode recorded at the inaugural SOHO UK 2026 meeting. The meeting was held in London March 3 and 4 at the Royal College of Physicians in London.

Dr. Iacoboni discussed strategies to improve outcomes in high-grade lymphoma, focusing on improved patient selection, the emergence of dual-targeted CAR T-cell products (CD19/CD20), and how circadian rhythms might impact infusion efficacy.

Follow more news from SOHO UK.

Prof. Amanda Goodall, director of the Executive Master’s in Medical Leadership (EMML), a specialized MSc degree from Bayes Business School offering advanced leadership training to medical doctors, joined SOHO Insider podcast host Prof. Christopher Fox, a professor of hematology at Nottingham University Hospitals NHS Trust, for a discussion on expert leadership in healthcare.

According to Prof. Goodall, expert leadership is the idea that organizations perform best when leaders are experts in the core work of the institution. As part of this work, she runs an executive master’s program in medical leadership, designed to help physicians develop the skills needed to lead healthcare organizations while maintaining credibility as clinicians.

Her research argues that in healthcare this means placing experienced, high-performing physicians in leadership roles rather than relying primarily on generalist managers. Many doctors, she noted, are interested in leadership because they want to drive meaningful change and improve patient care, but historically they have had limited access to formal leadership training.

The podcast was taped during the inaugural meeting of SOHO UK, where Prof. Goodall gave a talk after dinner on the topic.

Learn about the Executive Master’s in Medical Leadership (EMML) program.

Prof. Kate Cwynarski, MD, PhD, joined SOHO Insider podcast host Megan Melody, MD, for a discussion previewing lymphoma sessions she will lead at the inaugural SOHO UK meeting, scheduled for March 3–4, 2026, in London.

Prof. Cwynarski will chair a “Meet the Expert” roundtable on challenges and controversies in managing central nervous system (CNS) lymphoma. The session will include a seven-year update of the MARIETTA study, which examined treatment strategies for secondary CNS lymphoma, as well as findings from a large real-world evidence study of secondary CNS lymphoma.

She will also lead a session on peripheral T-cell lymphoma focused on the shift toward biologically informed therapy. The presentation will highlight the TERZO study and explore how emerging biologic insights may guide treatment decisions in this heterogeneous group of lymphomas.

The sessions are part of the program for the first SOHO UK meeting, which will bring together global clinicians and researchers to discuss advances in the treatment of blood cancers.

John DiPersio, MD, PhD, current president of SOHO and director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine in St. Louis, Missouri, discusses the need for public-private partnerships to move novel therapies forward in the treatment of blood cancers. He also speaks about how cross-sector collaboration can create better research paths for the future.

For SOHO 2026, Dr. DiPersio chose the theme “Advancing care through collaborative science,” a timely topic as NIH funding continues to decline.

“SOHO 2026 will explore how public-private partnerships can sustain discovery, preserve basic research, and ensure access to innovation for patients around the world,” Dr. DiPersio said in a recent interview with SOHO Insider.

Register today for SOHO 2026 at soho.click/2026. SOHO members receive a 40% discount. Join SOHO for free at http://soho.click/join.

In this podcast episode recorded at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Megan Melody, MD, from Tampa General Hospital, spoke with Tycel J. Phillips, MD, from the City of Hope Cancer Center, on the latest advancements in mantle cell lymphoma (MCL), including the phase 1/2 trial in relapsed or refractory MCL recently published in the Journal of Clinical Oncology.

In the trial led by Dr. Phillips, the investigators evaluated glofitamab monotherapy in patients with relapsed or refractory B-cell lymphomas, with obinutuzumab pretreatment to mitigate the risk of cytokine release syndrome with glofitamab.

Dr. Phillips also spoke about treating patients with relapsed or refractory non-Hodgkin lymphoma with venetoclax.

Listen to other podcast episodes of SOHO Insider.